Back to top
more

Century Therapeutics (IPSC)

(Delayed Data from NSDQ)

$1.22 USD

1.22
611,283

-0.04 (-3.17%)

Updated Nov 15, 2024 04:00 PM ET

After-Market: $1.22 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

What Makes Century Therapeutics (IPSC) a New Buy Stock

by Zacks Equity Research

Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Century Therapeutics (IPSC) delivered earnings and revenue surprises of 19.57% and 69.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

electroCore (ECOR) Stock Jumps 11.7%: Will It Continue to Soar?

by Zacks Equity Research

electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Century Therapeutics (IPSC) delivered earnings and revenue surprises of 24% and 40.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Century Therapeutics (IPSC) delivered earnings and revenue surprises of 10% and 185%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Amneal (AMRX) Stock Jumps 7.3%: Will It Continue to Soar?

by Zacks Equity Research

Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 193.4% in Century Therapeutics, Inc. (IPSC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Organogenesis (ORGO) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of 100% and 6.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of 10.42% and 4.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study

by Zacks Equity Research

Century (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%.

Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of -3.70% and 93.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -10.84% and 4.40%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 26.98% and 1.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 0% and 23.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 14.29% and 68.36%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of 4.17% and 4.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Plus (PSTV) delivered earnings and revenue surprises of 0% and 68.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 8.33% and 81.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC)

by Zacks Equity Research

Century Therapeutics, Inc. (IPSC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 10.17% and 42.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of -8% and 16.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?